Caristo Diagnostics provide advanced solutions for personalized cardiovascular risk prediction.
Their novel technology transforms the diagnostic accuracy of routine coronary CT angiograms, a test used to identify patients with suspected heart disease. Using artificial intelligence, their proprietary technology provides unique insights about inflammation in the coronary arteries, the root cause of most heart attacks.
Cardiovascular disease affects the heart and blood vessels and includes conditions such as angina and myocardial infarction (commonly known as a heart attack). According to the World Health Organisation1, cardiovascular diseases are the leading worldwide cause of death.
Caristo’s technology is based on a new scientific discovery: that the fat tissue surrounding the coronary arteries changes in response to inflammation inside the arteries. This change can be detected by their patented method for analysing the data produced in a routine test called Cardiac Computed Tomography Angiography (CCTA), producing a new measure called the Fat Attenuation Index (FAI™) which accurately quantifies the extent of inflammation in the coronary arteries supplying the heart.
CCTA (Cardiac Computed Tomography Angiography) is a non-invasive test that is routinely used by doctors throughout the world to look at your coronary arteries. CCTA has been recommended by the UK’s National Institute for Health and Care Excellence (NICE)4 as the first-line investigation for patients with stable chest pain. The beauty of Caristo’s technology is that FAI™ can be measured on any CCTA. You don’t need to have another test. You or your doctor can simply send them the CCTA that you have already had, and they can analyse it for you.
Caristo Diagnostics and NCIMI
Caristo Diagnostics has partnered with NCIMI to support expansion of the activity to develop and deploy our technology to assist clinicians in making personalized treatments decisions related to a patient’s future cardiac management.